163 related articles for article (PubMed ID: 19634915)
1. Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor.
Reddy LH; Renoir JM; Marsaud V; Lepetre-Mouelhi S; Desmaële D; Couvreur P
Mol Pharm; 2009; 6(5):1526-35. PubMed ID: 19634915
[TBL] [Abstract][Full Text] [Related]
2. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types.
Reddy LH; Dubernet C; Mouelhi SL; Marque PE; Desmaele D; Couvreur P
J Control Release; 2007 Dec; 124(1-2):20-7. PubMed ID: 17878060
[TBL] [Abstract][Full Text] [Related]
3. Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine.
Reddy LH; Marque PE; Dubernet C; Mouelhi SL; Desmaële D; Couvreur P
J Pharmacol Exp Ther; 2008 May; 325(2):484-90. PubMed ID: 18258784
[TBL] [Abstract][Full Text] [Related]
4. Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics.
Arias JL; Reddy LH; Othman M; Gillet B; Desmaële D; Zouhiri F; Dosio F; Gref R; Couvreur P
ACS Nano; 2011 Feb; 5(2):1513-21. PubMed ID: 21275408
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
[TBL] [Abstract][Full Text] [Related]
6. Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue.
Couvreur P; Reddy LH; Mangenot S; Poupaert JH; Desmaële D; Lepêtre-Mouelhi S; Pili B; Bourgaux C; Amenitsch H; Ollivon M
Small; 2008 Feb; 4(2):247-53. PubMed ID: 18247384
[TBL] [Abstract][Full Text] [Related]
7. Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice.
Reddy LH; Khoury H; Paci A; Deroussent A; Ferreira H; Dubernet C; Declèves X; Besnard M; Chacun H; Lepêtre-Mouelhi S; Desmaële D; Rousseau B; Laugier C; Cintrat JC; Vassal G; Couvreur P
Drug Metab Dispos; 2008 Aug; 36(8):1570-7. PubMed ID: 18474674
[TBL] [Abstract][Full Text] [Related]
8. A unique multidrug nanomedicine made of squalenoyl-gemcitabine and alkyl-lysophospholipid edelfosine.
Rodríguez-Nogales C; Sebastián V; Irusta S; Desmaële D; Couvreur P; Blanco-Prieto MJ
Eur J Pharm Biopharm; 2019 Nov; 144():165-173. PubMed ID: 31546021
[TBL] [Abstract][Full Text] [Related]
9. Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: study of mechanisms.
Reddy LH; Ferreira H; Dubernet C; Mouelhi SL; Desmaele D; Rousseau B; Couvreur P
Anticancer Drugs; 2008 Nov; 19(10):999-1006. PubMed ID: 18827565
[TBL] [Abstract][Full Text] [Related]
10. Squalenoyl nanomedicines as potential therapeutics.
Couvreur P; Stella B; Reddy LH; Hillaireau H; Dubernet C; Desmaële D; Lepêtre-Mouelhi S; Rocco F; Dereuddre-Bosquet N; Clayette P; Rosilio V; Marsaud V; Renoir JM; Cattel L
Nano Lett; 2006 Nov; 6(11):2544-8. PubMed ID: 17090088
[TBL] [Abstract][Full Text] [Related]
11. Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting.
Arias JL; Reddy LH; Couvreur P
Langmuir; 2008 Jul; 24(14):7512-9. PubMed ID: 18540685
[TBL] [Abstract][Full Text] [Related]
12. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
[TBL] [Abstract][Full Text] [Related]
13. Decoration of Squalenoyl-Gemcitabine Nanoparticles with Squalenyl-Hydroxybisphosphonate for the Treatment of Bone Tumors.
Rodríguez-Nogales C; Desmaële D; Sebastián V; Couvreur P; Blanco-Prieto MJ
ChemMedChem; 2021 Dec; 16(24):3730-3738. PubMed ID: 34581019
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic modalities of squalenoyl nanocomposites in colon cancer: an ongoing search for improved efficacy.
Maksimenko A; Alami M; Zouhiri F; Brion JD; Pruvost A; Mougin J; Hamze A; Boissenot T; Provot O; Desmaële D; Couvreur P
ACS Nano; 2014 Mar; 8(3):2018-32. PubMed ID: 24555414
[TBL] [Abstract][Full Text] [Related]
15. Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine.
Arias JL; Reddy LH; Couvreur P
J Drug Target; 2009 Sep; 17(8):586-98. PubMed ID: 19694612
[TBL] [Abstract][Full Text] [Related]
16. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes.
Bildstein L; Pili B; Marsaud V; Wack S; Meneau F; Lepêtre-Mouelhi S; Desmaële D; Bourgaux C; Couvreur P; Dubernet C
Eur J Pharm Biopharm; 2011 Nov; 79(3):612-20. PubMed ID: 21784150
[TBL] [Abstract][Full Text] [Related]
17. Interaction of a new anticancer prodrug, gemcitabine-squalene, with a model membrane: coupled DSC and XRD study.
Pili B; Bourgaux C; Amenitsch H; Keller G; Lepêtre-Mouelhi S; Desmaële D; Couvreur P; Ollivon M
Biochim Biophys Acta; 2010 Aug; 1798(8):1522-32. PubMed ID: 20435013
[TBL] [Abstract][Full Text] [Related]
18. A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity.
Maksimenko A; Dosio F; Mougin J; Ferrero A; Wack S; Reddy LH; Weyn AA; Lepeltier E; Bourgaux C; Stella B; Cattel L; Couvreur P
Proc Natl Acad Sci U S A; 2014 Jan; 111(2):E217-26. PubMed ID: 24385587
[TBL] [Abstract][Full Text] [Related]
19. Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation.
Pili B; Reddy LH; Bourgaux C; Lepêtre-Mouelhi S; Desmaële D; Couvreur P
Nanoscale; 2010 Aug; 2(8):1521-6. PubMed ID: 20820745
[TBL] [Abstract][Full Text] [Related]
20. Self-assembly of polyisoprenoyl gemcitabine conjugates: influence of supramolecular organization on their biological activity.
Lepeltier E; Bourgaux C; Maksimenko A; Meneau F; Rosilio V; Sliwinski E; Zouhiri F; Desmaële D; Couvreur P
Langmuir; 2014 Jun; 30(22):6348-57. PubMed ID: 24835925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
